What are the clinical benefits and potential disadvantages of switching from fedratinib to momelotinib in the management of myelofibrosis?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Switching from fedratinib to momelotinib in myelofibrosis management may enhance anemia control and symptom relief, though it carries potential disadvantages such as side effects and cost. Direct comparisons between these drugs are needed to better understand their relative benefits and risks.
Fields of Study & Subjects
Myeloproliferative Neoplasms: Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
Acute Myeloid Leukemia Research
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 26 March 2026
- Language
- EN